Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2018

Open Access 01-12-2018 | Research article

N-terminal pro-B-type natriuretic peptide and microsize myocardial infarction risk in the reasons for geographic and racial differences in stroke study

Authors: Madeline R. Sterling, Raegan W. Durant, Joanna Bryan, Emily B. Levitan, Todd M. Brown, Yulia Khodneva, Stephen P. Glasser, Joshua S. Richman, George Howard, Mary Cushman, Monika M. Safford

Published in: BMC Cardiovascular Disorders | Issue 1/2018

Login to get access

Abstract

Background

N-terminal pro B-type peptide (NT-proBNP) has been associated with risk of myocardial infarction (MI), but less is known about the relationship between NT-proBNP and very small non ST-elevation MI, also known as microsize MI. These events are now routinely detectable with modern troponin assays and are emerging as a large proportion of all MI. Here, we sought to compare the association of NT-proBNP with risk of incident typical MI and microsize MI in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Methods

The REGARDS Study is a national cohort of 30,239 US community-dwelling black and white adults aged ≥ 45 years recruited from 2003 to 2007. Expert-adjudicated outcomes included incident typical MI (definite/probable MI with peak troponin ≥ 0.5 μg/L), incident microsize MI (definite/probable MI with peak troponin < 0.5 μg/L), and incident fatal CHD. Using a case-cohort design, we estimated the hazard ratio of the outcomes as a function of baseline NT-proBNP. Competing risk analyses tested whether the associations of NT-proBNP differed between the risk of incident microsize MI and incident typical MI as well as if the association of NT-proBNP differed between incident non-fatal microsize MI and incident non-fatal typical MI, while accounting for incident fatal coronary heart disease (CHD) as well as heart failure (HF).

Results

Over a median of 5 years of follow-up, there were 315 typical MI, 139 microsize MI, and 195 incident fatal CHD. NT-proBNP was independently and strongly associated with all CHD endpoints, with significantly greater risk observed for incident microsize MI, even after removing individuals with suspected HF prior to or coincident with their incident CHD event.

Conclusion

NT-proBNP is associated with all MIs, but is a more powerful risk factor for microsize than typical MI.
Appendix
Available only for authorised users
Literature
2.
go back to reference de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345(14):1014–21.CrossRefPubMed de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345(14):1014–21.CrossRefPubMed
3.
go back to reference Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA. 2007;297(2):169–76.CrossRefPubMedPubMedCentral Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA. 2007;297(2):169–76.CrossRefPubMedPubMedCentral
4.
go back to reference Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352(7):666–75.CrossRefPubMed Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352(7):666–75.CrossRefPubMed
5.
go back to reference Di Angelantonio E, Chowdhury R, Sarwar N, et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation. 2009;120(22):2177–87.CrossRefPubMed Di Angelantonio E, Chowdhury R, Sarwar N, et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation. 2009;120(22):2177–87.CrossRefPubMed
6.
go back to reference Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004;110(20):3206–12.CrossRefPubMed Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004;110(20):3206–12.CrossRefPubMed
7.
go back to reference Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002;40(3):437–45.CrossRefPubMed Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002;40(3):437–45.CrossRefPubMed
8.
go back to reference Safford MM, Brown TM, Muntner PM, et al. Association of race and sex with risk of incident acute coronary heart disease events. JAMA. 2012;308(17):1768–74.CrossRefPubMedPubMedCentral Safford MM, Brown TM, Muntner PM, et al. Association of race and sex with risk of incident acute coronary heart disease events. JAMA. 2012;308(17):1768–74.CrossRefPubMedPubMedCentral
9.
go back to reference Bhatt H, Safford M, Glasser S. Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for geographic and racial differences in stroke (REGARDS) study. Curr Hypertens Rep. 2015;17(29):1–20. Bhatt H, Safford M, Glasser S. Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for geographic and racial differences in stroke (REGARDS) study. Curr Hypertens Rep. 2015;17(29):1–20.
10.
go back to reference Mills NLLK, McAllister DA, et al. Implications of lowering threshold of plasma troponin concentration in diagnosis of myocardial infarction: cohort study. The BMJ. 2012;344:e1533. The BMJ. 2012;e1533:344. Mills NLLK, McAllister DA, et al. Implications of lowering threshold of plasma troponin concentration in diagnosis of myocardial infarction: cohort study. The BMJ. 2012;344:e1533. The BMJ. 2012;e1533:344.
11.
go back to reference Morrow DA. Evidence-based decision limits for cardiac troponin: low-level elevation and prognosis. Am Heart J. Vol 148. United States2004:739–742. Morrow DA. Evidence-based decision limits for cardiac troponin: low-level elevation and prognosis. Am Heart J. Vol 148. United States2004:739–742.
12.
go back to reference Mills NL, Churchhouse AM, Lee KK, et al. Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA. 2011;305(12):1210–6.CrossRefPubMed Mills NL, Churchhouse AM, Lee KK, et al. Implementation of a sensitive troponin I assay and risk of recurrent myocardial infarction and death in patients with suspected acute coronary syndrome. JAMA. 2011;305(12):1210–6.CrossRefPubMed
13.
go back to reference Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001;286(19):2405–12.CrossRefPubMed Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001;286(19):2405–12.CrossRefPubMed
14.
go back to reference Howard VJ, Cushman M, Pulley L, et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology. 2005;25(3):135–43.CrossRefPubMed Howard VJ, Cushman M, Pulley L, et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology. 2005;25(3):135–43.CrossRefPubMed
15.
go back to reference Cushman M, McClure LA, Howard VJ, Jenny NS, Lakoski SG, Howard G. Implications of increased C-reactive protein for cardiovascular risk stratification in black and white men and women in the US. Clin Chem. 2009;55(9):1627–36.CrossRefPubMedPubMedCentral Cushman M, McClure LA, Howard VJ, Jenny NS, Lakoski SG, Howard G. Implications of increased C-reactive protein for cardiovascular risk stratification in black and white men and women in the US. Clin Chem. 2009;55(9):1627–36.CrossRefPubMedPubMedCentral
16.
go back to reference Cushman M, Callas PW, McClure LA, et al. N-terminal pro-B-type natriuretic peptide and risk of future cognitive impairment in the REGARDS cohort. Journal of Alzheimer's disease : JAD. 2016; Cushman M, Callas PW, McClure LA, et al. N-terminal pro-B-type natriuretic peptide and risk of future cognitive impairment in the REGARDS cohort. Journal of Alzheimer's disease : JAD. 2016;
17.
go back to reference Zhang ZM, Prineas RJ, Eaton CB. Evaluation and comparison of the Minnesota Code and Novacode for electrocardiographic Q-ST wave abnormalities for the independent prediction of incident coronary heart disease and total mortality (from the Women's Health Initiative). The American journal of cardiology. 2010;106(1):18–25.e12. Zhang ZM, Prineas RJ, Eaton CB. Evaluation and comparison of the Minnesota Code and Novacode for electrocardiographic Q-ST wave abnormalities for the independent prediction of incident coronary heart disease and total mortality (from the Women's Health Initiative). The American journal of cardiology. 2010;106(1):18–25.e12.
18.
go back to reference Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on epidemiology and prevention; AHA statistics committee; world heart federation council on epidemiology and prevention; the European Society of Cardiology Working Group on epidemiology and prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation. 2003;108(20):2543–9.CrossRefPubMed Luepker RV, Apple FS, Christenson RH, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on epidemiology and prevention; AHA statistics committee; world heart federation council on epidemiology and prevention; the European Society of Cardiology Working Group on epidemiology and prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation. 2003;108(20):2543–9.CrossRefPubMed
19.
go back to reference Prineas RCR, Blackburn H. The Minnesota code manual of electrocardiographic findings: standards and procedures for measurement and classification. Boston, MA: Wright-OSG; 1982. Prineas RCR, Blackburn H. The Minnesota code manual of electrocardiographic findings: standards and procedures for measurement and classification. Boston, MA: Wright-OSG; 1982.
21.
go back to reference Safford MM, Parmar G, Barasch CS, et al. Hospital laboratory reporting may be a barrier to detection of ‘microsize’ myocardial infarction in the US: an observational study. BMC Health Serv Res Vol 132013:162. Safford MM, Parmar G, Barasch CS, et al. Hospital laboratory reporting may be a barrier to detection of ‘microsize’ myocardial infarction in the US: an observational study. BMC Health Serv Res Vol 132013:162.
22.
go back to reference Galasko GI, Lahiri A, Barnes SC, Collinson P, Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J. 2005;26(21):2269–76.CrossRefPubMed Galasko GI, Lahiri A, Barnes SC, Collinson P, Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J. 2005;26(21):2269–76.CrossRefPubMed
24.
go back to reference Prentice RL, Pyke R. Logistic disease incidence models and case-control studies. Biometrika. 1979;66(3):403–11.CrossRef Prentice RL, Pyke R. Logistic disease incidence models and case-control studies. Biometrika. 1979;66(3):403–11.CrossRef
25.
go back to reference Onland-Moret NC, van der AD, van der Schouw YT, et al. Analysis of case-cohort data: a comparison of different methods. J Clin Epidemiol. 2007;60(4):350–5.CrossRefPubMed Onland-Moret NC, van der AD, van der Schouw YT, et al. Analysis of case-cohort data: a comparison of different methods. J Clin Epidemiol. 2007;60(4):350–5.CrossRefPubMed
26.
go back to reference Cushman M, Judd SE, Howard VJ, et al. N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort. Stroke. 2014;45(6):1646–50.CrossRefPubMedPubMedCentral Cushman M, Judd SE, Howard VJ, et al. N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort. Stroke. 2014;45(6):1646–50.CrossRefPubMedPubMedCentral
27.
go back to reference Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol. 1999;52(12):1165–72.CrossRefPubMed Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol. 1999;52(12):1165–72.CrossRefPubMed
28.
29.
go back to reference Rubin DBSN. Multiple imputation in health-care databases: an overview and some applications. Stat Med. 1991;10:585–98.CrossRefPubMed Rubin DBSN. Multiple imputation in health-care databases: an overview and some applications. Stat Med. 1991;10:585–98.CrossRefPubMed
30.
go back to reference Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation. 2007;116(22):2634–53.CrossRefPubMed Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation. 2007;116(22):2634–53.CrossRefPubMed
31.
go back to reference Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551–67.CrossRefPubMed Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551–67.CrossRefPubMed
32.
33.
go back to reference Konstam MA. Natriuretic peptides and cardiovascular events: more than a stretch. Jama. Vol 297. United States2007:212–214. Konstam MA. Natriuretic peptides and cardiovascular events: more than a stretch. Jama. Vol 297. United States2007:212–214.
34.
go back to reference Mills NL, Lee KK, McAllister DA, et al. Implications of lowering threshold of plasma troponin concentration in diagnosis of myocardial infarction: cohort study. BMJ (Clinical research ed). 2012;344:e1533.CrossRef Mills NL, Lee KK, McAllister DA, et al. Implications of lowering threshold of plasma troponin concentration in diagnosis of myocardial infarction: cohort study. BMJ (Clinical research ed). 2012;344:e1533.CrossRef
35.
go back to reference Bonaca M, Scirica B, Sabatine M, et al. Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. J Am Coll Cardiol. 2010;55(19):2118–24.CrossRefPubMed Bonaca M, Scirica B, Sabatine M, et al. Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. J Am Coll Cardiol. 2010;55(19):2118–24.CrossRefPubMed
36.
go back to reference Pastormerlo LE, Maffei S, Della Latta D, Chubuchny V, Susini C, Berti S, Clerico A, Prontera C, Passino C, Januzzi JL, Emdin M. N-terminal prob-type natriuretic peptide is a marker of vascular remodelling and subclinical atherosclerosis in asymptomatic hypertensives. Eur J Prev Cardiol. 2016;23(4):366–76.CrossRefPubMed Pastormerlo LE, Maffei S, Della Latta D, Chubuchny V, Susini C, Berti S, Clerico A, Prontera C, Passino C, Januzzi JL, Emdin M. N-terminal prob-type natriuretic peptide is a marker of vascular remodelling and subclinical atherosclerosis in asymptomatic hypertensives. Eur J Prev Cardiol. 2016;23(4):366–76.CrossRefPubMed
37.
go back to reference Hopkins WE, Chen Z, Fukagawa NK, Hall C, Knot HJ, LeWinter MM. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation. 2004;109(23):2872–7.CrossRefPubMed Hopkins WE, Chen Z, Fukagawa NK, Hall C, Knot HJ, LeWinter MM. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation. 2004;109(23):2872–7.CrossRefPubMed
38.
go back to reference Tateishi JMM, Ohyanagi M, Iwasaki T. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol. 2000;23:776–80.CrossRefPubMed Tateishi JMM, Ohyanagi M, Iwasaki T. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol. 2000;23:776–80.CrossRefPubMed
39.
go back to reference Goetze JPGA, Moller CH, Steinbruchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. FASEB J. 2004;18:1928–30.CrossRefPubMed Goetze JPGA, Moller CH, Steinbruchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. FASEB J. 2004;18:1928–30.CrossRefPubMed
40.
go back to reference Min NLP, Khaper N, Liu P. Inflammatory cytokines and Postmyocardial Infarcation remodeling. Circ Res. 2004;94:1543–53.CrossRef Min NLP, Khaper N, Liu P. Inflammatory cytokines and Postmyocardial Infarcation remodeling. Circ Res. 2004;94:1543–53.CrossRef
41.
go back to reference Tsuruda T, Boerrigter G, Huntley BK, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res. 2002;91(12):1127–34.CrossRefPubMed Tsuruda T, Boerrigter G, Huntley BK, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res. 2002;91(12):1127–34.CrossRefPubMed
42.
43.
go back to reference Luchner A, Hengstenberg C, Lowel H, Riegger GA, Schunkert H, Holmer S. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension (Dallas, Tex. : 1979). 2005;46(1):118–23. Luchner A, Hengstenberg C, Lowel H, Riegger GA, Schunkert H, Holmer S. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension (Dallas, Tex. : 1979). 2005;46(1):118–23.
44.
go back to reference Dadu RT, Fornage M, Virani SS, et al. Cardiovascular biomarkers and subclinical brain disease in the atherosclerosis risk in communities study. Stroke. 2013;44(7):1803–8.CrossRefPubMedPubMedCentral Dadu RT, Fornage M, Virani SS, et al. Cardiovascular biomarkers and subclinical brain disease in the atherosclerosis risk in communities study. Stroke. 2013;44(7):1803–8.CrossRefPubMedPubMedCentral
45.
go back to reference Mutlu U, Ikram MA, Hofman A, de Jong PT, Klaver CC, Ikram MK. N-terminal pro-B-type natriuretic peptide is related to retinal microvascular damage: the Rotterdam study. Arterioscler Thromb Vasc Biol. 2016;36(8):1698–702.CrossRefPubMed Mutlu U, Ikram MA, Hofman A, de Jong PT, Klaver CC, Ikram MK. N-terminal pro-B-type natriuretic peptide is related to retinal microvascular damage: the Rotterdam study. Arterioscler Thromb Vasc Biol. 2016;36(8):1698–702.CrossRefPubMed
46.
go back to reference Bower JK, Lazo M, Matsushita K, et al. N-terminal pro-brain natriuretic peptide (NT-proBNP) and risk of hypertension in the atherosclerosis risk in communities (ARIC) study. Am J Hypertens. 2015;28(10):1262–6.CrossRefPubMedPubMedCentral Bower JK, Lazo M, Matsushita K, et al. N-terminal pro-brain natriuretic peptide (NT-proBNP) and risk of hypertension in the atherosclerosis risk in communities (ARIC) study. Am J Hypertens. 2015;28(10):1262–6.CrossRefPubMedPubMedCentral
47.
go back to reference Natriuretic Peptides Studies C, Willeit P, Kaptoge S, et al. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. The lancet. Diabetes & endocrinology. 2016;4(10):840–9. Natriuretic Peptides Studies C, Willeit P, Kaptoge S, et al. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. The lancet. Diabetes & endocrinology. 2016;4(10):840–9.
48.
go back to reference Abdullah SM, Khera A, Das SR, et al. Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas heart study). Am J Cardiol. 2005;96(9):1284–9.CrossRefPubMed Abdullah SM, Khera A, Das SR, et al. Relation of coronary atherosclerosis determined by electron beam computed tomography and plasma levels of n-terminal pro-brain natriuretic peptide in a multiethnic population-based sample (the Dallas heart study). Am J Cardiol. 2005;96(9):1284–9.CrossRefPubMed
49.
go back to reference Gan L, Feng C, Liu C, Tian S, Song X, Yang L. Association between serum N-terminal pro-B-type natriuretic peptide levels and characteristics of coronary atherosclerotic plaque detected by coronary computed tomography angiography. Experimental and therapeutic medicine. 2016;12(2):667–75.CrossRefPubMedPubMedCentral Gan L, Feng C, Liu C, Tian S, Song X, Yang L. Association between serum N-terminal pro-B-type natriuretic peptide levels and characteristics of coronary atherosclerotic plaque detected by coronary computed tomography angiography. Experimental and therapeutic medicine. 2016;12(2):667–75.CrossRefPubMedPubMedCentral
50.
go back to reference Ndrepepa G, Braun S, Mehilli J, et al. Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. Am J Cardiol. 2005;95(5):553–7.CrossRefPubMed Ndrepepa G, Braun S, Mehilli J, et al. Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. Am J Cardiol. 2005;95(5):553–7.CrossRefPubMed
Metadata
Title
N-terminal pro-B-type natriuretic peptide and microsize myocardial infarction risk in the reasons for geographic and racial differences in stroke study
Authors
Madeline R. Sterling
Raegan W. Durant
Joanna Bryan
Emily B. Levitan
Todd M. Brown
Yulia Khodneva
Stephen P. Glasser
Joshua S. Richman
George Howard
Mary Cushman
Monika M. Safford
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2018
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-018-0806-4

Other articles of this Issue 1/2018

BMC Cardiovascular Disorders 1/2018 Go to the issue